PPM1D as a novel biomarker for prostate cancer after radical prostatectomy
- PMID: 24922655
PPM1D as a novel biomarker for prostate cancer after radical prostatectomy
Abstract
Protein phosphatase magnesium-dependent 1 delta (PPM1D) is involved in several types of cancer. The current study examined the role of PPM1D expression in prostate cancer (PCa) tissues and in PCa cell lines. Expression of PPM1D was evaluated using immunohistochemistry in 234 PCa tissues after radical prostatectomy and 80 benign prostatic hyperplasia (BPH) tissues. The associations of PPM1D expression with clinicopathological parameters and survival were analyzed. In vitro, tumor cells were transfected with small interfering RNA targeting PPM1D (siPPM1D) or si-Scramble, and the cell proliferation, migration and invasion were determined. We found that PPM1D expression was significantly higher in PCa tissues than that in BPH tissues. PPM1D expression was positively correlated with Gleason score (p=0.022), T stage (p=0.015) and lymph node status (p=0.016). Kaplan-Meier curve analysis showed that patients with positive PPM1D expression had shorter biochemical recurrence-free survival and overall survival. Furthermore, multivariate analyses showed that PPM1D expression was an independent predictor of both biochemical recurrence-free (hazard ratio=3.437, 95% confidence interval=1.154-6.209, p=0.016) and overall survival (hazard ratio=5.026, 95% confidence interval=2.545-8.109, p=0.007). Knockdown of PPM1D inhibited the proliferation, migration and invasion capabilities of PC-3 and LNCaP cells. PPM1D expression may predict for both overall and biochemical recurrence-free survival in patients after radical prostatectomy for PCa. Elevated PPM1D expression plays a key role in progression of PCa.
Keywords: PPM1D; biomarker; prognosis; prostate cancer.
Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.
Similar articles
-
Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.Mol Med Rep. 2015 Jul;12(1):1298-304. doi: 10.3892/mmr.2015.3455. Epub 2015 Mar 9. Mol Med Rep. 2015. PMID: 25760033
-
Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy.Cancer Biomark. 2016;16(3):351-8. doi: 10.3233/CBM-160573. Cancer Biomark. 2016. PMID: 26889981
-
Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy.Int J Mol Sci. 2016 Jul 23;17(8):1194. doi: 10.3390/ijms17081194. Int J Mol Sci. 2016. PMID: 27455254 Free PMC article.
-
The association of CXCR4 expression with clinicopathological significance and potential drug target in prostate cancer: a meta-analysis and literature review.Drug Des Devel Ther. 2015 Sep 7;9:5115-22. doi: 10.2147/DDDT.S82475. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26379424 Free PMC article. Review.
-
Impact of Immunohistochemical Biomarkers on Predicting the Risk of Biochemical Recurrence for Patients that Underwent Radical Prostatectomy: A Literature Review.Arch Esp Urol. 2024 Aug;77(7):718-725. doi: 10.56434/j.arch.esp.urol.20247707.100. Arch Esp Urol. 2024. PMID: 39238294 Review.
Cited by
-
SOD1 is a synthetic lethal target in PPM1D-mutant leukemia cells.bioRxiv [Preprint]. 2024 Jan 17:2023.08.31.555634. doi: 10.1101/2023.08.31.555634. bioRxiv. 2024. Update in: Elife. 2024 Jun 18;12:RP91611. doi: 10.7554/eLife.91611 PMID: 37693622 Free PMC article. Updated. Preprint.
-
PPM1D in Solid and Hematologic Malignancies: Friend and Foe?Mol Cancer Res. 2022 Sep 2;20(9):1365-1378. doi: 10.1158/1541-7786.MCR-21-1018. Mol Cancer Res. 2022. PMID: 35657598 Free PMC article.
-
SOD1 is a synthetic-lethal target in PPM1D-mutant leukemia cells.Elife. 2024 Jun 18;12:RP91611. doi: 10.7554/eLife.91611. Elife. 2024. PMID: 38896450 Free PMC article.
-
Wild-type p53-induced phosphatase 1 is a prognostic marker and therapeutic target in bladder transitional cell carcinoma.Oncol Lett. 2017 Feb;13(2):875-880. doi: 10.3892/ol.2016.5475. Epub 2016 Dec 8. Oncol Lett. 2017. PMID: 28356972 Free PMC article.
-
The role of PPM1D in cancer and advances in studies of its inhibitors.Biomed Pharmacother. 2020 May;125:109956. doi: 10.1016/j.biopha.2020.109956. Epub 2020 Jan 29. Biomed Pharmacother. 2020. PMID: 32006900 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical